SCHEMBL6985685

SCHEMBL6985685

CC1=CC(=O)CC(c2cccc(Cl)c2)N1C(=O)C(F)(F)F

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 3/20 0.44
PDE5A O76074 1/20 0.40
MAOA P21397 3/20 0.39
MAOB P27338 3/20 0.39
TP53 P04637 1/20 0.39
PTPN11 Q06124 1/20 0.38
ESR1 P03372 1/20 0.38
ESR2 Q92731 1/20 0.38
KIF11 P52732 1/20 0.38
GSK3B P49841 1/20 0.37
CACNA1F O60840 1/20 0.37
CACNA1D Q01668 1/20 0.37
CACNA1S Q13698 1/20 0.37
CACNA1C Q13936 1/20 0.37
ADAM17 P78536 1/20 0.36
PRKCZ Q05513 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7592025 0.85 MAOA (0.44) RIPK1PDE5AMAOAMAOBTP53
SCHEMBL7592028 0.85 MAOA (0.44) RIPK1PDE5AMAOAMAOBTP53
SCHEMBL6985269 0.77 CHRNA7 (0.45) RIPK1MAOAMAOBPRKCZ
Hydrochloric Acid SCHEMBL7590235 0.67 RIPK1 (0.44) RIPK1PDE5AMAOAMAOBPTPN11
Hydrochloric Acid SCHEMBL7590233 0.67 RIPK1 (0.44) RIPK1PDE5AMAOAMAOBPTPN11
SCHEMBL1097647 0.65 P2RX7 (0.45) PDE5AMAOAMAOBKIF11GSK3B
SCHEMBL7684882 0.64 RIPK1 (0.42) RIPK1PDE5AMAOAMAOBKIF11
SCHEMBL7684879 0.64 RIPK1 (0.42) RIPK1PDE5AMAOAMAOBKIF11
SCHEMBL6978662 0.63 MAPT (0.43) TP53HTT
SCHEMBL6981391 0.63 MAPT (0.43) TP53HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1050530-B1 1-Aza-2-alkyl-6-aryl-cycloalkanes usefull as memory enhancers SERVIER LAB (FR) 2003-10-22 EP disclosed
US-6451789-B1 CENTRAL NERVOUS SYSTEM DISORDERS; COGNITION ACTIVATORS LES LABORTOIRES SERVIER (FR) 2002-09-17 US disclosed
US-20020042413-A1 1-aza-2-alkyl-6-aryl-cycloalkanes RAULT SYLVAIN (FR) 2002-04-11 US disclosed
US-6323222-B1 COGNITION ACTIVATORS, ALZHEIMER*S DISEASE AND ENZYME INHIBITORS ADIR ET COMPAGNIE (FR) 2001-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042413-A1 1-aza-2-alkyl-6-aryl-cycloalkanes SULT2A1, GRIN2A, NR3C1 RIPK1 4845/4885PDE5A 2668/4885MAOA 468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.